Interleukin-2 and subunit alpha of its soluble receptor in autoimmune Addison's disease – An association study and expression analysis

References

• Irvine, W. J., and A. G. Stewart. 1967. A clinical and immunological study of adrenocortical insufficiency (Addison's disease). Clin. Exp. Immunol. 2: 31–38
   PubMedGoogle Scholar
• Winqvist, O., F. A. Karlsson, and O. Kampe. 1992. 21-hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet. 339: 1559–1562
   PubMed Web of Science ®Google Scholar
• Skinningsrud, B., B. A. Lie, E. Lavant, et al. 2011. Multiple loci in the HLA complex are associated with Addison's disease. J. Clin. Endocrinol. Metab. 96: E1703–E1708
   PubMedGoogle Scholar
• Mitchell, A. L., and S. H. Pearce. 2012. Autoimmune Addison disease: pathophysiology and genetic complexity. Nat. Rev. Endocrinol. 8: 306–316
   PubMedGoogle Scholar
• Vang, T., A. V. Miletic, N. Bottini, and T. Mustelin. 2007. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity. 40: 453–461
   PubMed Web of Science ®Google Scholar
• Mitchell, A. L., K. D. Macarthur, E. H. Gan, et al. 2014. Association of autoimmune Addison's disease with alleles of STAT4 and GATA3 in European cohorts. PLoS One. 9: e88991
   Google Scholar
• Morgan, D. A., F. W. Ruscetti, and R. Gallo. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 193: 1007–1008
   PubMed Web of Science ®Google Scholar
• Kriegel, M. A., T. Lohmann, C. Gabler, et al. 2004. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 199: 1285–1291
   PubMed Web of Science ®Google Scholar
• Sadlack, B., J. Lohler, H. Schorle, et al. 1995. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25: 3053–3059
   PubMed Web of Science ®Google Scholar
• Wang, X., M. Rickert, and K. C. Garcia. 2005. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma receptors. Science. 310: 1159–1163
   PubMed Web of Science ®Google Scholar
• Malek, T. R, and I. Castro. 2010. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 33(2): 153–165
   PubMed Web of Science ®Google Scholar
• Caudy, A. A., S. T. Reddy, T. Chatila, et al. 2007. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enetropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J. Allergy Clin. Immunol. 119: 482–487
   PubMed Web of Science ®Google Scholar
• Zhernakova, A., B. Z. Alizadeh, M. Bevova, et al. 2007. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am. J. Hum. Genet. 81: 1284–1288
   PubMed Web of Science ®Google Scholar
• Wellcome Trust Case Control Consortium. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447: 661–678
   PubMed Web of Science ®Google Scholar
• Maier, L. M., C. E. Lowe, J. Cooper, et al. 2009. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5: e1000322
   PubMed Web of Science ®Google Scholar
• Maiti, A. K., X. Kim-Howard, P. Viswanathan, et al. 2010. Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum. 62: 323–329
   PubMed Web of Science ®Google Scholar
• Espino-Paisan, L., H. De La Calle, M. Fernandez-Arquero, et al. 2011. Study of polymorphisms in 4q27, 10p15, and 22q13 regions in autoantibodies stratified type 1 diabetes patients. Autoimmunity. 44: 624–630
   PubMed Web of Science ®Google Scholar
• Van Heel, D. A., L. Franke, K. A. Hunt, et al. 2007. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet. 39: 827–829
   PubMed Web of Science ®Google Scholar
• Festen, E. A., P. Goyette, R. Scott, et al. 2009. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut. 58: 779–804
   Google Scholar
• Brand, O. J., C. E. Lowe, J. M. Heward, et al. 2007. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin. Endocrinol. (Oxf) 66: 508–512
   PubMed Web of Science ®Google Scholar
• Skinningsrud, B., E. S. Husebye, S. H. Pearce, et al. 2008. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 93: 3310–3317
   PubMedGoogle Scholar
• Fichna, M., M. Zurawek, P. Fichna, et al. 2012. Increased serum osteoprotegerin in patients with primary adrenal insufficiency receiving conventional hydrocortisone substitution. J. Physiol. Pharmacol. 63: 677–682
   PubMedGoogle Scholar
• Asawa, T., N. Wedlock, A. Baumann-Antczak, et al. 1994. Adrenal autoantibodies and naturally occurring mutations in 21-hydroxylase. Autoimmunity. 17: 339–341
   PubMed Web of Science ®Google Scholar
• Matesanz, F., M. Fedetz, L. Leyva, et al. 2004. Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression. J. Neuroimmunol. 148: 212–217
   PubMed Web of Science ®Google Scholar
• Todd, J. A., N. M. Walker, J. D. Cooper, et al. 2007. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39: 857–864
   PubMed Web of Science ®Google Scholar
• Qu, H. Q., A. Montpetit, B. Ge, et al. 2007. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes. 56: 1174–1176
   PubMed Web of Science ®Google Scholar
• Lowe, C. E., J. D. Cooper, T. Brusko, et al. 2007. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat. Genet. 39: 1074–1082
   PubMed Web of Science ®Google Scholar
• Garg, G., J. R. Tyler, J. H. Yang, et al. 2012. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J. Immunol. 188: 4644–4653
   PubMed Web of Science ®Google Scholar
• Bratland, E., G. Bredholt, G. Mellgren, et al. 2009. The purification and application of biologically active recombinant steroid cytochrome P450 21-hydroxylase: the major autoantigen in autoimmune Addison's disease. J. Autoimmun. 33: 58–67
   PubMedGoogle Scholar
• Owen, C. J., H. Kelly, J. A. Eden, et al. 2007. Analysis of the Fc receptor-like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association. J. Clin. Endocrinol. Metab. 92: 1106–1111
   PubMed Web of Science ®Google Scholar
• Zurawek, M., M. Fichna, D. Januszkiewicz-Lewandowska, et al. 2010. A coding variant in NLRP1 is associated with autoimmune Addison's disease. Hum. Immun. 71: 530–534
   PubMedGoogle Scholar
• Fedetz, M., D. Ndagire, O. Fernandez, et al. 2009. Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population. Tissue Antigens. 74: 244–247
   PubMed Web of Science ®Google Scholar
• Erlich, H. A., A. M. Valdes, C. Julier, et al. 2009. Evidence for association of the TCF7 locus with type I diabetes. Genes Immun. 10: S54–S59
   Google Scholar
• Cerosaletti, K., A. Schneider, K. Schwedhelm, et al. 2013. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS One. 8: e83811
   PubMed Web of Science ®Google Scholar
• Sauer, J., M. Rupprecht, E. Arzt, et al. 1993. Glucocorticoids modulate soluble interleukin-2 receptor levels in vivo depending on the state of immune activation and the duration of glucocorticoid exposure. Immunopharamacology. 25: 269–276
   PubMedGoogle Scholar
• Sauer, J., G. K. Stalla, O. A. Muller, and E. Arzt. 1994. Inhibition of interleukin-2-mediated lymphocyte activation in patients with Cushing's syndrome: a comparison with hypocortisolemic patients. Neuroendocrinology. 59: 144–151
   PubMedGoogle Scholar
• Kretowski, A., J. Mysliwiec, M. Szelachowska, et al. 1999. In vitro secretion of interleukin 2 and expression of IL-2 receptor in peripheral blood lymphocytes in high risk of insulin-dependent diabetes mellitus subjects. Arch. Immunol. Ther. Exp. (Warsz). 47: 45–49
   PubMedGoogle Scholar
• Boscaro, M., C. Betterle, M. Volpato, et al. 1996. Hormonal responses during various phases of autoimmune adrenal failure: no evidence for 21-hydroxylase enzyme activity inhibition in vivo. J. Clin. Endocrinol. Metab. 81: 2801–2804
   PubMed Web of Science ®Google Scholar
• Bratland, E., B. Skinningsrud, D. E. Undlien, et al. 2009. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 94: 5117–5124
   PubMedGoogle Scholar
• Rottembourg, D., C. Deal, M. Lambert, et al. 2010. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison's disease. J. Autoimmun. 35: 309–315
   PubMedGoogle Scholar
• Nagel, J. E., R. K. Chopra, F. J. Chrest, et al. 1988. Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors. J. Clin. Invest. 81: 1096–1102
   PubMedGoogle Scholar
• Laureti, S., A. De Bellis, V. I. Muccitelli, et al. 1998. Levels of adrenocortical antibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J. Clin. Endocrinol. Metab. 83: 3507–3511
   PubMedGoogle Scholar
• Betterle, C., F. Zanette, R. Zanchetta, et al. 1983. Complement-fixing adrenal autoantibodies as a marker for predicting onset of idiopathic Addison's disease. Lancet. 1: 1238–1241
   PubMed Web of Science ®Google Scholar